Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat switch study in pulmonary arterial hypertension patients not at treatment goal on PDE-5 inhibitor therapy
2016-001067-36Phase 4Completed
- Sponsor
- Bayer
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of riociguat in pulmonary arterial hypertension (PAH), sponsored by Bayer. Started Sep 2016; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2016-001067-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001067-36.